Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that involves multiple systems throughout the body. The prevalence in China is 0.7-1/1,000, and it is estimated that there are more than 1 million patients nationwide. SLE was once considered an “incurable disease”, but in recent years, with the increase in the means of early diagnosis of SLE and the improvement in the level of treatment, its prognosis has been greatly improved. In China, the 1-year, 5-year and 10-year survival rates are about 98%, 86% and 76%. The vast majority of patients can live and work like normal people after regular treatment. Therefore, standardized individual treatment is imperative and is the way to long-term remission for patients. The clinical manifestations of lupus erythematosus are diverse. Light patients only show fever, rash, photosensitivity, arthritis, Raynaud’s phenomenon, a small amount of plasma cavity effusion or mild leukopenia, without obvious visceral damage. Severe patients have involvement of one or several organs such as lupus nephritis, lupus encephalopathy, acute vasculitis, interstitial pneumonia, hemolytic anemia, thrombocytopenic purpura, and massive plasma membrane cavity effusion. To truly achieve individualized treatment, it is not only necessary for the doctor to use symptom-relieving treatment according to the patient’s condition at the time. It is also necessary to quickly determine the prognosis of the disease according to the condition, formulate a treatment plan to improve the long-term prognosis, and adjust the treatment immediately according to the regression of the disease and adverse reactions during the follow-up treatment in the future, so as to achieve the best efficacy with the least side effects and the lowest cost, and benefit the patients for a lifetime. The current treatment plan of SLE includes the following aspects: 1. Glucocorticoids (hormones for short): Many patients have strong resistance to hormones because they are worried about their side effects. In fact, hormone is a “double-edged sword” in the treatment of SLE. With reasonable dosage, correct usage and early reduction of dosage, the treatment effect will be good and no obvious side effects will occur; on the contrary, the side effects of hormone will cause harm to patients. Clinicians choose the right dose of hormone according to the severity of the patient’s condition, and add immunosuppressant treatment after the clinical symptoms are relieved to maximize the efficacy and minimize the adverse effects. Immunosuppressants and antimalarials: Immunosuppressants have anti-inflammatory and immunosuppressive effects. Combining small doses of immunosuppressants with hormone therapy can reduce hormone dosage, alleviate hormone side effects and delay organ damage. Commonly used immunosuppressants include cyclophosphamide, cyclosporine A, azathioprine, methotrexate, morte-macrolide, tacrolimus, etc. Antimalarials include chloroquine and hydroxychloroquine. Severe lupus or lupus nephritis is usually treated with cyclophosphamide and hormones. Azathioprine is more commonly used in the maintenance treatment of lupus nephritis. Hydroxychloroquine and methotrexate have relatively few side effects and are usually used for the treatment of mild to moderate lupus, and antimalarials have no adverse effects on pregnant women and fetuses. Plasma exchange: Plasma exchange treatment can remove abnormal antibodies in the blood, and is most effective for patients with lupus erythematosus who have significantly increased antinuclear antibodies and immunoglobulins in the blood and are more severe. However, hormone and immunosuppressive therapy are still needed. 4. Other new treatments: T-cell vaccines, biological agents such as Abciap, hematopoietic stem cell transplantation, and mesenchymal stem cell therapy for lupus have also achieved certain efficacy. It should be noted that the above is only a brief introduction to the current treatment of lupus erythematosus, and it is recommended that patients must visit the rheumatology department of regular hospitals when adjusting their treatment and follow medical advice to adjust their medication. Lifestyle adjustments such as reducing ultraviolet radiation and preventing infections are also key to controlling and stabilizing the condition of lupus erythematosus.